ReviewCurrent urology reports2012
The role of neuromodulation in patients with neurogenic overactive bladder.
Review in Current urology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- EAU-ESPU-ERN eUROGEN-ERN ITHACA-ERN ERKNet-IFSBH Guidelines on Spinal Dysraphism in Children and Adolescents: Summary of the Guideline.European urology open science · 2026Article
- Flat Magnetic Stimulation in the Conservative Management of Mild Pelvic Organ Prolapse: A Retrospective Observational Study.Medicina (Kaunas, Lithuania) · 2025Observational
- Neurogenic bladder pathophysiology, assessment and management after lumbar diseases.EFORT open reviews · 2025Review
- Neuromodulation - a therapeutic option for refractory overactive bladder. A recent literature review.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2019Review
- "A secret club": focus groups about women's toileting behaviors.BMC women's health · 2019Article
- Detecting Bladder Biomarkers for Closed-Loop Neuromodulation: A Technological Review.International neurourology journal · 2018Article
- Neuromodulation in neurogenic bladder.Translational andrology and urology · 2016Review
- Sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction.Spinal cord · 2016Article
- Urinary considerations for adult patients with spinal dysraphism.Nature reviews. Urology · 2015Review
- Neurogenic bladder - concepts and treatment recommendations.International braz j urol : official journal of the Brazilian Society of UrologyReview
- Nocturia in Parkinson's Disease: Why Does It Occur and How to Manage?Movement disorders clinical practiceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To review the treatment options for patients with neurogenic overactive bladder (OAB), specifically the use of sacral neuromodulation (SNM). A search was performed on the available literature on SNM and lower urinary tract dysfunction. Based on published studies available and also on personal experience, the treatment options for neurogenic OAB are reviewed, and specifically, the role for SNM in these patients is discussed. SNM is FDA-approved for patients with urge incontinence, urgency/frequency, and non-obstructive urinary retention. It involves stimulation of the third sacral nerve with an electrode implanted in the sacral foramen and connected to a pulse generator. The procedure is minimally invasive and is effective in about 70 % of patients who have a permanent system. The original trials leading to the approval of SNM excluded patients with neurogenic disease, as it was felt that intact spinal pathways were necessary for neuromodulation to occur. However, similar success rates have been observed in patients with neurogenic OAB. Special considerations for SNM use in patients with neurogenic OAB include recognizing that it is incompatible for patients who will need MRI's due to their progressive neurologic disease. Many treatment options are available for patients with neurogenic OAB. First-line approaches remain conservative with lifestyle changes and anticholinergic medications. SNM has been used successfully in this patient population with good results, though larger randomized trials are lacking.
Indexed as
Identifiers
22865208What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.